NMDA-antagonism (memantine): An alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia

Current Pharmaceutical Design

Volumn 10, Issue 3, 2004, Pages 253-259

  Koch, Horst J ^a   Szecsey, Alexander ^a   Haen, Ekkehard ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BARBITURIC ACID DERIVATIVE; CALCIUM ION; CHOLINESTERASE INHIBITOR; CIMETIDINE; GLUTAMIC ACID; HYDROCHLOROTHIAZIDE; KETAMINE; LEVODOPA; MAGNESIUM ION; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHENYTOIN; TRIAMTERENE;

AGED; AGITATION; ALZHEIMER DISEASE; CALCIUM TRANSPORT; CELL MEMBRANE DEPOLARIZATION; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HALLUCINATION; HEADACHE; HUMAN; MALE; MULTIINFARCT DEMENTIA; NAUSEA; NERVE CELL PLASTICITY; NEUROTRANSMISSION; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SLEEP DISORDER; STEADY STATE;

ALZHEIMER DISEASE; CLINICAL TRIALS; DEMENTIA, VASCULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GLUTAMIC ACID; HUMANS; MEMANTINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0346025494     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043386392     Document Type: Review

References (89)

1. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Eur J Pharmacol 1991; 206: 297.
2. Bormann J. Eur J Pharmacol 1989; 166: 591.
3. Szatkowski M, Attwell D. Trends Neurosci 1994; 17: 359.
4. Bormann J, Gold M, Schatton W. European Patent Office 1993; no 39: 20-59 BI.
5. Patent vascular.
6. Frölich L, Fox JM, Padberg F, Maurer K, Möller HJ, Hampel H. Curr Pharm Design: 2001.
7. Danysz W, Parsons CG, Möbius HJ, Stöffler A, Quack G. Neurotox Res 2000; 2: 85.
8. Greenamyre JT, Young AB, Penny JB. J Neurosci 1984; 4: 2133.
9. Palmer AM, Gershon S. FASEB J 1990; 4: 2745.
10. Ibach B. Acetylchinesterase Inhibitors Curr Pharm Design 2001.
11. Li S, Mallory M, Alford M, Tanaka S, Masliah E. J Neuropathol Exp Neurol 1997; 56: 901.
12. Arias C, Arrieta I, Tapia R. J Neurosci Res 1995; 41: 561.
13. Harris ME, Wang YN, Pedigo NW, Hensley K, Butterfield DA, Carney JM. J Neurochem 1996; 67: 277.
14. Klegeris A, McGeer PL. J Neurosci Res 1997; 49: 229.
15. Noda M, Nakanishi H, Akaike N. Neuroscience 1999; 92: 1465.
16. Masliah E, Mallory M, Alford M, Tanaka S, Hansen LA. J Neuropathol Exp Neurol 1998; 57: 1041.
17. Giulian D, Haverkamp LJ, Li J, Karshin WL, Yu J, Tom D. et al. NeurochemInt 1995; 27: 119.
18. Goodwin JL, Uemura E, Cunnick JE. Brain Res 1995; 692: 207.
19. Lees GJ. Neuroscience 1993; 54: 287.
20. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. J Neurosci 1992; 12: 376.
21. Harkany T, Abraham I, Timmerman W, Laskay G, Toth B, Sasvari M, et al. Eur J Neurosci, 2000; 12: 2735.
22. Wu JQ, Anwyl R, Rowan MJ. Neuroreport 1995; 6: 2409.
23. Cowburn RF, Wiehager B, Trief E, LiLi M, Sundstrom E. Neurochem Res 1997; 22: 1437.
24. Cullen WK, Wu JQ, Anwyl R, Rowan MJ. Neuroreport 1996; 8: 87.
25. Couratier P, Sindou P, Tabaraud E, Diop AG, Spencer PS, Hugon J. Neurodegeneration 1995; 4: 33.
26. Couratier P, Lesort M, Sindou P, Esclaire F, Yardin C, Hugon J. Mol Chem Neuropathol 1996; 27: 259.
27. Couratier P, Lesort M, Terro F, Dussartre C, Hugon J. Fund Clin Pharmacol 1996; 10: 344.
28. Pizzi M, Valerio A, Arrighi V, Galli P, Belloni M, Ribola M, et al. Eur J Neurosci 1995; 7: 1603.
29. Topper R, Gehrmann J, Banati R, Schwarz M, Block F, Noth J, et al. Acta Neuropathol 1995; 89: 23.
30. Braak H, Braak E, Bohl J. Eur Neurol 1993; 33: 403.
31. Francis PT, Sims NR, Procter AW, Bowen DM. J Neurochem 1993; 60: 1589.
32. Mortimer JA, VanDuijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, et al. Int J Epidemiol 1991; 20 (Suppl 2) S28-S35.
33. Mendez MF, Underwood KL, Zander BA, Mastri AR, Sung JH, Frey WH. Neurology 1992; 42: 770.
34. Backhauss C, Karkoutly C, Welsch M, Krieglstein J. J Pharmacol Toxicol Meth 1992; 27: 27.
35. Chen HSV, Wang YF, Rayudu PV, Edgecomb P, Neill JC, Segal MM, et al. Neuroscience 1998; 86: 1121.
36. Block F, Schwarz M. Neurosci Lett 1996 208: 41.
37. Seif El Nasr M, Peruche B, Rossberg C, Mennel HD, Krieglstein J, Share NN. Eur J Pharmacol 1990; 185: 19.
38. Chen HSV, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, et al. J Neurosci 1992; 12: 4427.
39. Heim C, Sontag K-H. J Neural Transm 1995; 46: 117.
40. Danysz W, Zajaczkowski W, Parsons CG. Behav Pharmacol 1995; 6:455.
41. Parsons CG, Danysz W, Quack G. Drug News Perspect 1998; 11: 523.
42. Collingridge GL, Singer W. Trends Pharmacol Sci 1990; 11: 290.
43. Clements JD, Lester RAJ, Tong G, Jahr CE, Westbrook GL. Science 1992; 258: 1498.
44. Nowak L, Bregestovski P, Ascher P, Herbert A, Prochiantz A. Nature 1984; 307: 462.
45. Globus MYT, Busto R, Dietrich WD, Martinez E, Valdes I, Ginsberg MD. J Neurochem 1988; 51: 1455.
46. Parsons CG, Gruner R, Rozental J, Millar J, Lodge D. Neuropharmacology 1993; 32: 1337.
47. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, et al. Neuropharmacology 1995; 34: 1239.
48. Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA. Eur J Neurosci 1996; 8: 446.
49. Frankiewicz T, Parsons CG. Neuropharmacology 1999; 38: 1253.
50. Kornhuber J, Weller M, Schoppmeyer K, Riederer P. J Neural Transm 1994; Suppl, 43: 91.
51. Parsons CG, Danysz W, Bartmann A, Spielmanns P, Frankiewicz T, Hesselink M, et al. Neuropharmacology 1999; 38: 85.
52. Parsons CG, Danysz W, Quack G. Neuropharmacology 1999; 38: 735.
53. Zajaczkowski W, Frankiewicz T, Parsons CG, Danysz W. Neuropharmacology 1997; 36: 961.
54. Izumi Y, Clifford DB, Zorumski CF. Neurosci Lett 1992; 137: 245.
55. Coan EJ, Irving AJ, Collingridge GL. Neurosci Lett 1989; 105: 205.
56. Rothman SM, Olney JW. Trends Neurosci 1987; 10: 299.
57. Choi DW. Trends Neurosci 1995; 18: 58.
58. Misztal M, Filipkowski RK, Kaczmarek L, Skangiel-Kramska J, Danysz W. Behav Pharmacol 1994; 5 (Suppl 1) 55.
59. Wenk GL, Danysz W, Mobley SL. Brain Res 1994; 655: 7.
60. Wenk GL, Danysz W, Mobley SL. Eur J Pharmac Env Tox Pharmacol 1995; 293: 267.
61. Wenk GL, Danysz W, Roice DD. Neuroreport 1996; 7: 1453.
62. Schulz JB, Matthews RT, Henshaw DR, Beal MF. Neuroscience 1996; 71: 1043.
63. Willard LB, Hauss-Wegrzyniak B, Danysz W, Wenk GL. Exp Brain Res 2000; 134: 58.
64. Miguel-Hidalgo JJ, Alvarez XA, Quack G, Cacabelos R. Neurobiol Aging 1998; 19: 542.
65. Reisberg B. Neurobiol Aging 2000; 21: S275.
66. Wilcock G [Abstract] 6th IntlSpringfield Symposium Stockholm 2000.
67. Orgogozo J-M. Forette FftM3g [Abstract] Sixth IntStockholm/Sprinfield Symposium on Advances in Alzheimer Therapy April 5-8 2000.
68. Winblad B, Poritis N. International Journal of Geriatric Psychiatry 1999; 14: 135.
69. Ditzler K. Arzneimittelforschung 1991; 8: 773.
70. Pantev M, Ritter R, Görtelmeyer R. Zeitschrift für Gerontopsychologie und -psychiatrie 1993; 6: 103-117.
71. Wimo A, Winblad B. Curr Pharm Design: 2001.
72. Rüther E, Glaser A, Bleich S, Degner D, Wiltfang J. Pharmacopsychiatry 2000; 33: 103.
73. Sahin K, Stoeffler A, Furtuna P, Rosenwald D, Moebius H-J. Neurobiology of Aging 2000; 21: Suppl 1: 527.
74. Wilcock G, Stoeffler A, Sahin K, Möbius H-J. J Eur Coll Neuropsychopharmacol 2000; 10: Suppl 3: 360.
75. MRC CFAS Neuropathology Group Lancet 2001; 357: 169-179.
76. Freudenthaler S, Meineke I, Schreeb KH, Boakye E, Gundert-Remy U, Gleiter CH. Br J Clin Pharmacol 1998; 46: 541.
77. Riederer P, Lange KW, Kornhuber J, Danielczyk W. Lancet 1991; 338: 1022.
78. Young BK, Camicioli R, Ganzini L. Drug Aging 1997; 10: 367.
79. Wenk GL, Quack G, Moebius HJ, Danysz W. Life Sci 2000; 66: 1079.
80. Bruder J. 1994 6th Int Workshop on Amantadin Prague 10th - 12th March personal communication.
81. Fünfgeld EW. MedKlin 1985; 80(20) 559.
82. Noth J. JNeurol 1991; 238(3) 131.
83. Schulz H, Jobert M, Coppola R, Herrmann WM, Pantev M. Neuropsychobiology: 1996; 33(1) 32.
84. Ambrozi L, Danielczyk W. Pharmacopsychiatry 1988; 21(3): 144;
85. Starck M, Albrecht H, Pollmann W, Straube A, Dieterich M J Neurology 1997; 244 (1) 9.
86. Herrmann WM, Kern U, Rohmel J. Pharmacopsychiatry: 1986; 19: 378.
87. Danysz W, Parsons C. G, Jirgensons A, Kauss V, Tillner J. Aminoalkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists. Curr Pharm Design 2002; 8(10): 835-43.
88. Nikam S. S. and Meltzer L. T. NR2B selective NMDA receptor antagonists. Curr Pharm Design 2002; 8(10): 845-55.
89. Weiser T. AMPA receptor antagonists with additional mechanisms of action: new opportunities for neuroprotective drugs? Curr Pharm Design 2002; 8(10): 941-51.